Pfizer, BioNTech to supply 120 mn doses of coronavirus vaccine to Japan

BioNTech and Pfizer on Monday began a large, late-stage trial of their vaccine candidate to demonstrate its efficacy

Pfizer Inc and BioNTech SE have agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021, the companies said on Friday.

The companies did not disclose the financial details of the agreement, but said terms were based on the volume of doses and the timing of the delivery.

The United States has signed a similar deal with Pfizer and BioNtech for 100 million doses for nearly $2 billion, which amounts to a $39 price tag for what is likely to be a two-dose treatment course.